The impact of hormonal treatments on quality of life of patients with metastatic breast cancer

Clinical Therapeutics

Volumn 24, Issue SUPPL. C, 2002, Pages

  Costantino, J ^a,b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Advanced breast cancer; Endocrine therapy; Estrogen receptor antagonists; Quality of life

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; ANTIESTROGEN; AROMATASE; AROMATASE INHIBITOR; EXEMESTANE; FULVESTRANT; GESTAGEN; LETROZOLE; MEDROXYPROGESTERONE; MEGESTROL ACETATE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TOREMIFENE; VOROZOLE; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER HORMONE THERAPY; CLINICAL TRIAL; DISTRESS SYNDROME; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG TOLERABILITY; FEMALE; HUMAN; MOTOR DYSFUNCTION; PHASE 3 CLINICAL TRIAL; QUALITY OF LIFE; RISK BENEFIT ANALYSIS; THROMBOEMBOLISM; TREATMENT OUTCOME; VAGINA BLEEDING; VAGINA DISCHARGE; BREAST TUMOR; METASTASIS; REVIEW;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CLINICAL TRIALS; FEMALE; HUMANS; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 0036045795     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(02)85159-1     Document Type: Article

References (31)

1. Comparison of two quality-of-life instruments for cancer patients: The Functional Assessment of Cancer Therapy-General and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30
2. Health outcomes and quality of life
3. Endocrine therapy in the treatment of metastatic breast cancer
4. Treatment of breast cancer
5. The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology
6. Tamoxifen for the prevention of breast cancer: Psychosocial impact on women participating in two randomized controlled trials
7. Health-related quality of life and tamoxifen in breast cancer prevention: A report from the National Surgical Adjuvant Breast and Bowel Project P-1 study
8. Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument
9. Assessment of quality of life in women undergoing hormonal therapy for breast cancer: Validation of an endocrine symptom subscale for the FACT-B
10. A phase III comparison of two toremifene doses to tamoxifen in postmenopausal women with advanced breast cancer
11. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: Results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study
12. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: Results of a North American multicenter randomized trial
13. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: Results of a phase III study of the International Letrozole Breast Cancer Group
14. A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma
15. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: Double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate
16. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: Results of a phase III randomized double-blind trial
17. Fulvestrant
18. Randomized phase III trial comparing the new potent and selective third-generation aromatase inhibitor vorozole with megestrol acetate in postmenopausal advanced breast cancer patients
19. Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer
20. Comparison of toremifene and tamoxifen in post-menopausal patients with advanced breast cancer: A randomized double-blind, the 'Nordic' phase III study
21. Phase III randomized trial of toremifene vs tamoxifen in hormonodependent advanced breast cancer
22. A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer
23. Fulvestrant
24. A review of endocrine options for the treatment of advanced breast cancer
25. Psychosocial quality of life in a phase III trial of letrozole
26. Femara®: Preservation of quality of life in women undergoing second line hormonotherapy for breast cancer in a three month period
27. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: A phase II trial
28. Effect of endocrine treatment on sexuality in premenopausal breast cancer patients: A prospective randomized study
29. Effect of tamoxifen on sexual functioning in patients with breast cancer
30. Improved quality of life during clonidine treatment for tamoxifen-induced hot flashes: A URCC CCOP study
31. Preliminary analysis of the pilot study using gabapentin on tamoxifen-induced hot flashes in women with breast cancer